Seattle Genetics is an innovative biotechnology firm based in Seattle, Washington. They focus on creative cancer treatments utilizing empowered monoclonal antibodies. They are best known for creating a specific type of empowered monoclonal antibody called ADC, or Antibody Drug Conjugates. ADCs are molecules that consist of both an antibody and anti-cancer substance. These treatments pinpoint cancer cells more precisely, preventing damage to healthy cells that is associated with other treatment modalities.
Seattle Genetics’ best known product is an ADC called Adcetris, a treatment for Hodgkin’s Lymphoma. Due to its impressive efficacy, it was fast-tracked for approval by the FDA in 2011. Approved for use in Europe and Australia, Adcetris is in use worldwide. In addition to Adcetris, Seattle has cooperated with a host of companies to produce other treatments. These partnerships have yielded revenues of nearly a billion dollars for the relatively new company.
Seattle Genetics Co-Founder Appointed to Board of Directors for Mirna Therapeutics Inc.
The company was co-founded in 1988 by Clay Siegall, a distinguished researcher who had previously worked at Bristol-Myers Squibb and the National Institutes of Health. He serves as the President, CEO, and Chairman of the Board of Directors. Siegall secured hundreds of millions of dollars in funding and led the company to its IPO in 2001. In addition to heading up Seattle Genetics, Siegall is on the board of directors of several major biotechnology companies and research organizations.